Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

NCT04812002 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Gestational Trophoblastic Neoplasia

Interventions

DRUG: PD-1 inhibitor， bevacizumab

Sponsor

Women's Hospital School Of Medicine Zhejiang University